Novo Nordisk’s weight loss injection, Wegovy, could potentially thwart 1.5 million heart attacks and strokes over 10 years, according to a recent study, reports CNBC.
Researchers from the University of California, Irvine discovered that Wegovy could also result in 43 million fewer Americans with obesity over the same timeframe. The study was partially financed by Novo Nordisk.
The results of the research support the initial data from the Danish company’s recent clinical trial, which found that Wegovy reduced the risk of serious heart issues and heart-related death by 20%.
These findings suggest that Wegovy, Ozempic and other similar obesity drugs could provide significant health benefits beyond just being ‘miracle’ weight loss drugs. This could potentially exert more pressure on insurers to cover obesity medications, which currently cost more than $1,000 per month.
Image via Shutterstock
Engineered by Benzinga Neuro, Edited by Pooja Rajkumari
The GPT-4 Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. Learn more.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
